Alpha Cognition (ACOG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual General Meeting scheduled for June 16, 2026, at Timarron Country Club, Southlake, TX.
Proxy materials, including the proxy statement and annual report, are available online or by request.
Securityholders are encouraged to review all proxy materials before voting.
Voting matters and shareholder proposals
Shareholders will vote on setting the number of directors, electing directors, and appointing independent auditors.
Board recommends voting "FOR" all resolutions and director nominees.
Board of directors and corporate governance
Election of directors is a key agenda item for the meeting.
The number of directors constituting the board will be set by shareholder vote.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Alpha Cognition
- Q2 2026 revenue up 71% QoQ and 268% YoY to $6.0–$6.1M; net loss narrows to $8.8M.ACOG
Q2 2026 - ZUNVEYL posts rapid growth in prescriptions and revenue, targeting a $2B LTC market.ACOG
Corporate presentation - Q1 2026 revenue grew 40% to $3.5M, with strong adoption and a widened net loss on higher costs.ACOG
Q1 2026 - Shareholders will vote on board composition, auditor appointment, and executive compensation.ACOG
Proxy filing - ZUNVEYL's rapid growth and LTC focus drive strong revenue and market expansion.ACOG
Corporate presentation - 2025 revenue hit $10.2M with rapid ZUNVEYL adoption and $66M cash supporting 2027 profitability.ACOG
Q4 2025 - Biopharma seeks up to $250M to fund Alzheimer's drug launch and pipeline, with $75M ATM offering.ACOG
Registration Filing - FDA-approved ZUNVEYL launches in March, targeting LTC Alzheimer's with improved tolerability.ACOG
Investor Update - ZUNVEYL launched in the US, $52.8M raised, and global expansion underway.ACOG
Q4 2024